Safety of Blood Stem Cell Mobilization With Plerixafor in Patients With Sickle Cell Disease

Summary

The objective of this study is to investigate if up to two injections of plerixafor represent a safe and effective strategy to mobilize adequate numbers of CD34+ hematopoietic stem progenitor cells (HSPC) for autologous hematopoietic cell transplantation (HCT) in sickle cell disease (SCD) patients

Timeline

Start

2018-09-19

Primary completion

2026-08-03

Completion

2026-08-03

Drugs

Indications